[Left ventricular hypertrophy in hemodialysis patient: Prevalence, electrocardiographic, echocardiographic study and associated risk factors].

Hypertrophie ventriculaire gauche chez les hémodialysés : prévalence, étude électrique, échographique et facteurs de risque.
Echocardiography Electrocardiogramme Electrocardiography Hemodialysis Hypertrophie myocardique Hémodialyse Insuffisance rénale Myocardial hypertrophy Renal failure Échocardiographie

Journal

Nephrologie & therapeutique
ISSN: 1872-9177
Titre abrégé: Nephrol Ther
Pays: France
ID NLM: 101248950

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 05 09 2021
revised: 12 10 2021
accepted: 13 10 2021
pubmed: 27 1 2022
medline: 27 7 2022
entrez: 26 1 2022
Statut: ppublish

Résumé

Left ventricular hypertrophy is the most prevalent cardiac abnormality in hemodialysis patients. The diagnosis of this abnormality is possible by electrocardiogram and/or echocardiography. Our study aimed to assess the prevalence of left ventricular hypertrophy in hemodialysis patients and the accuracy of different electrocardiographic criteria. This was a cross-sectional retrospective study including 60 hemodialysis patients between 2017 and 2018. A left ventricular mass index higher than 115g/m This was a cohort of 60 patients composed of 27 men and 33 women with a mean age 52.6±15,8years. Hypertension was the most common cardiovascular risk factor (82 %). The prevalence of left ventricular hypertrophy at echography was 65 %. Prevalence of left ventricular hypertrophy at electrocardiographic varied across the different criteria ranging from 5 % (R wave in DI) to 32 % (Perugia score). The highest left ventricular hypertrophy prevalence at electrocardiographic was found with the five following criteria: Perugia score (32 %), Peguero-Lo Presti index (28 %), Sokolow-Lyon index, Cornell index, Framingham-adjusted Cornell voltage (17 %). Sensitivity was ranged from 5 % (R in DI, Gubner-Ungerleider index, and product) to 41 % (Perugia score). The specificity of most criteria was ≥90 % except for the Perugia score (85 %). The sensitivity, specificity, postitive and negative productive values and left ventricular hypertrophy prevalence using the five most accurate criteria combined were respectively 48, 90, 70.28, 77.85 and 33 %. Hypertension, duration of HD, arteriovenous fistula, interdialytic weight gain, systolic blood pressure, hemoglobin <9g/dL and hyperparathyroidism were significantly associated with left ventricular hypertrophy. The prevalence of left ventricular hypertrophy detected by echocardiography was high. All electrocardiographic criteria had a low sensibility and a high specificity in the diagnostic of echocardiographic left ventricular hypertrophy. To improve the accuracy of electrocardiographic criteria, it is necessary to combine several electrocardiographic criteria and not often focused on a single classic electrocardiographic index.

Sections du résumé

BACKGROUND BACKGROUND
Left ventricular hypertrophy is the most prevalent cardiac abnormality in hemodialysis patients. The diagnosis of this abnormality is possible by electrocardiogram and/or echocardiography. Our study aimed to assess the prevalence of left ventricular hypertrophy in hemodialysis patients and the accuracy of different electrocardiographic criteria.
METHODS METHODS
This was a cross-sectional retrospective study including 60 hemodialysis patients between 2017 and 2018. A left ventricular mass index higher than 115g/m
RESULTS RESULTS
This was a cohort of 60 patients composed of 27 men and 33 women with a mean age 52.6±15,8years. Hypertension was the most common cardiovascular risk factor (82 %). The prevalence of left ventricular hypertrophy at echography was 65 %. Prevalence of left ventricular hypertrophy at electrocardiographic varied across the different criteria ranging from 5 % (R wave in DI) to 32 % (Perugia score). The highest left ventricular hypertrophy prevalence at electrocardiographic was found with the five following criteria: Perugia score (32 %), Peguero-Lo Presti index (28 %), Sokolow-Lyon index, Cornell index, Framingham-adjusted Cornell voltage (17 %). Sensitivity was ranged from 5 % (R in DI, Gubner-Ungerleider index, and product) to 41 % (Perugia score). The specificity of most criteria was ≥90 % except for the Perugia score (85 %). The sensitivity, specificity, postitive and negative productive values and left ventricular hypertrophy prevalence using the five most accurate criteria combined were respectively 48, 90, 70.28, 77.85 and 33 %. Hypertension, duration of HD, arteriovenous fistula, interdialytic weight gain, systolic blood pressure, hemoglobin <9g/dL and hyperparathyroidism were significantly associated with left ventricular hypertrophy.
CONCLUSION CONCLUSIONS
The prevalence of left ventricular hypertrophy detected by echocardiography was high. All electrocardiographic criteria had a low sensibility and a high specificity in the diagnostic of echocardiographic left ventricular hypertrophy. To improve the accuracy of electrocardiographic criteria, it is necessary to combine several electrocardiographic criteria and not often focused on a single classic electrocardiographic index.

Identifiants

pubmed: 35078738
pii: S1769-7255(21)00543-5
doi: 10.1016/j.nephro.2021.10.003
pii:
doi:

Types de publication

Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

247-254

Informations de copyright

Copyright © 2021. Published by Elsevier Masson SAS.

Auteurs

Soumaya Chargui (S)

Service de médecine interne A, hôpital Charles Nicolle, Tunis, Tunisie; Laboratoire de recherche de pathologie rénale (LR00SP01), Tunis, Tunisie. Electronic address: chargui.souma@yahoo.fr.

Emna Allouche (E)

Service de cardiologie, hôpital Charles Nicolle, Tunis, Tunisie.

Wiem Dkhil (W)

Faculté de médecine de Tunis, Tunis, Tunisie.

Sahar Agrebi (S)

Service de médecine interne A, hôpital Charles Nicolle, Tunis, Tunisie; Laboratoire de recherche de pathologie rénale (LR00SP01), Tunis, Tunisie.

Habib Ben Ahmed (H)

Service de cardiologie, hôpital Charles Nicolle, Tunis, Tunisie.

Khaled Ezzaouia (K)

Service de cardiologie, hôpital Charles Nicolle, Tunis, Tunisie.

Mariem Hajji (M)

Service de médecine interne A, hôpital Charles Nicolle, Tunis, Tunisie.

Asma Ezzamouri (A)

Service de médecine, hôpital régional de Djerba, Djerba, Tunisie.

Leila Basdah (L)

Service de cardiologie, hôpital Charles Nicolle, Tunis, Tunisie.

Fethi Ben Hamida (F)

Laboratoire de recherche de pathologie rénale (LR00SP01), Tunis, Tunisie.

Amel Harzallah (A)

Service de médecine interne A, hôpital Charles Nicolle, Tunis, Tunisie; Laboratoire de recherche de pathologie rénale (LR00SP01), Tunis, Tunisie.

Ezzeddine Abderrahim (E)

Service de médecine interne A, hôpital Charles Nicolle, Tunis, Tunisie.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH